8-K: Protagenic Therapeutics Announces 1-for-14 Reverse Stock Split to Comply with Nasdaq Minimum Bid Price Rule

Protagenic Therapeutics' Board of Directors has approved a 1-for-14 reverse stock split, effective May 5, 2025, to meet Nasdaq's minimum bid price requirement.

Summary

• Protagenic Therapeutics has announced a 1-for-14 reverse stock split of its common stock.
• The reverse stock split will be effective on May 5, 2025, at 12:01 a.m. Eastern Time.
• The company's common stock will continue to trade on the Nasdaq Capital Market under the symbol PTIX.
• The primary reason for the reverse stock split is to comply with Nasdaq's minimum bid price requirement for continued listing.
• The reverse stock split was approved by stockholders on April 18, 2025, with a ratio range of 1-for-10 to 1-for-20.
• The reverse stock split will reduce the number of outstanding shares from approximately 8,242,510 to approximately 588,750, subject to adjustments for fractional shares.
• Proportionate adjustments will be made to exercise prices and the number of shares underlying outstanding equity awards and equity incentive plans.
• Fractional shares resulting from the reverse stock split will be rounded up to the next whole share.
• Stockholders holding shares in book-entry form do not need to take any action.
• Stockholders of record will receive information from the company's transfer agent, Equiniti Trust Company, LLC, regarding their post-reverse stock split ownership.
• Stockholders holding certificates will receive a letter of transmittal from Equiniti with instructions on how to surrender their pre-split certificates.
• The new CUSIP number for the common stock following the reverse stock split is 74365N301.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the reverse stock split is a measure to maintain Nasdaq listing, it's often viewed as a sign of underlying issues with the stock price. The company is taking necessary steps to remain compliant, but the long-term impact is uncertain.

Positives

• The reverse stock split is intended to ensure continued listing on the Nasdaq Capital Market.
• Stockholders holding shares in book-entry form do not need to take any action.
• Fractional shares will be rounded up to the next whole share, which is favorable to shareholders.

Negatives

• The reverse stock split reduces the number of outstanding shares, which can be perceived negatively by some investors.
• Reverse stock splits are often implemented when a company's stock price is low, which can be a sign of financial distress.

Risks

• The company's prospects are subject to uncertainties and risks, as highlighted in the forward-looking statements disclaimer.
• The company's actual results could differ materially from the forward-looking statements due to various business risks and uncertainties.
• The reverse stock split may not be sufficient to maintain compliance with Nasdaq listing requirements if the stock price does not increase.

Future Outlook

The company expects its common stock to open for trading on a post-split basis on Nasdaq as of the commencement of trading on May 5, 2025. The reverse stock split is intended to bring the company into compliance with the minimum bid price requirement for continued listing on Nasdaq.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low stock prices. This action aims to increase the stock price to meet minimum listing requirements and potentially improve investor perception.

Comparison to Industry Standards

• Reverse stock splits are a relatively common practice among companies listed on exchanges like Nasdaq and NYSE when they are at risk of falling below minimum share price requirements.
• Many companies in the biotechnology and pharmaceutical industries, particularly smaller firms with volatile stock prices, have used reverse stock splits to maintain their listing status.
• For example, companies like BioTime and Agenus have previously implemented reverse stock splits to comply with Nasdaq's minimum bid price rule.
• The success of a reverse stock split in maintaining listing and improving investor confidence depends on the company's underlying financial health and future prospects.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they hold, but the proportionate value should remain the same immediately following the split.
• The reverse stock split aims to maintain the company's listing on Nasdaq, which could positively impact investor confidence.
• Employees may be affected by the company's overall financial health and stock performance.

Next Steps

• The company will implement the reverse stock split on May 5, 2025.
• The company's transfer agent, Equiniti Trust Company, LLC, will provide information to stockholders regarding their post-reverse stock split ownership.
• Stockholders holding certificates will receive a letter of transmittal from Equiniti with instructions on how to surrender their pre-split certificates.

Key Dates

Keywords

reverse stock split, Protagenic Therapeutics, PTIX, Nasdaq, minimum bid price, compliance, common stock, stockholders